Individualization of valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant patients

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 326-330

  Zhao, Wei ^a,b   Fakhoury, May ^a   Fila, Marc ^a   Baudouin, Véronique ^a   Deschênes, Georges ^a   Jacqz Aigrain, Evelyne ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

Author keywords

Ganciclovir; Individualized therapy; Kidney transplantation; Pediatric pharmacology pharmacokinetics; Pediatrics; Population pharmacokinetics; Valganciclovir

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACCURACY; ADOLESCENT; ANALYTIC METHOD; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CALCULATION; CHILD; CHILD CARE; CLINICAL ARTICLE; COMPARTMENT MODEL; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; EXTERNAL VALIDITY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SAMPLING;

ADOLESCENT; ANTIVIRAL AGENTS; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY TRANSPLANTATION; MALE; PROSPECTIVE STUDIES;

EID: 84861229225     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182509e3a     Document Type: Article

References (20)

1. Valcytlabel information. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/021304s008, 022257s003lbl.pdf. Updated May 8, 2010. Accessed October 1, 2011.
2. Kim I, Chu XY, Kim S, et al. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biochem. 2003;278:25348-25356. (Pubitemid 36835284)
3. Lai L, Xu Z, Zhou J, et al. Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem. 2008;283:9318-9327.
4. Perrottet N, Decosterd LA, Meylan P, et al. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet. 2009;48:399-418.
5. Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter-and intrapatient variability of ganciclovir levels in children. Pediatr Transplant. 2007;11:301-305. (Pubitemid 46570151)
6. Zhao W, Baudouin V, Zhang D, et al. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet. 2009;48:321-328.
7. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636-943.
8. FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm225727.htm. Accessed October 1, 2011.
9. Luck S, Lovering A, Griffiths P, et al. Ganciclovir treatment in children: evidence of subtherapeutic levels. Int J Antimicrob Agents. 2011;37: 445-448.
10. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711-721.
11. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005;79:1477-1483. (Pubitemid 40847577)
12. Zhao W, Cella M, Della Pasqua O, et al. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV infected infants and toddlers. Br J Clin Pharmacol. doi: 10.1111/j.1365-2125.2011.04121.x.
13. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant. 2009;9:636-643.
14. Zhang D, Lapeyraque AL, Popon M, et al. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol. 2003;18: 943-948. (Pubitemid 37121631)
15. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit. 2010;32:688-699.
16. Zhao W, Fakhoury M, Baudouin V, et al. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. Ther Drug Monit. 2011;33:681-687.
17. Zhao W, Jacqz-Aigrain E. Principles of therapeutic drug monitoring. Handb Exp Pharmacol. 2011;205:77-90.
18. Neely M, Jelliffe R. Practical therapeutic drug management in HIVinfected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48:1081-1091.
19. Adachi M, Sampath J, Lan LB, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem. 2002;277:38998-39004. (Pubitemid 35154766)
20. Sugawara M, Huang W, Fei YJ, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000;89:781-789.